Clinical trials: Stenosis Progression
Atherosclerosis, Chronic Kidney Disease
Revascularization of Renal Artery Stenosis Versus Medical Therapy for the Treatment of Ischemic Nephropathy
The aim of the study is to value, in patients with chronic kidney disease and hypertension, whether medical therapy plus interventional renal artery revascularization is superior to medical therapy alone for the treatment of…
- Conditions
- Atherosclerosis, Chronic Kidney Disease, Hypertension, Renovascular, Ischemic Nephropathy
- Trial name
- NITER (NCT01023373)
- Testing
- Medical treatment, PTRS, renal artery stent
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Azienda Unita Sanitaria Locale di Piacenza
Moderate Aortic Valve Stenosis, Moderate Aortic Valve Regurgitation
Prospective Observational Cohort Study of Moderate Aortic Valve Disease
The objective of this research is to evaluate and predict the progression of moderate aortic stenosis and regurgitation from clinical characterization, biological, echocardiographic, and computed tomography (CT) et. al.
- Conditions
- Moderate Aortic Valve Stenosis, Moderate Aortic Valve Regurgitation, Aortic Valve Disease
- Trial name
- NCT06595992
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Aortic Valve Disease, Aortic Valve Stenosis
Colchicine and Inflammation in Aortic Stenosis
Aortic stenosis (AS) is the most common valvular heart disease in the developed world. Once symptomatic, untreated patients have a poor prognosis with five-year survival rate of 25%.
- Conditions
- Aortic Valve Disease, Aortic Valve Stenosis, Aortic Valve Calcification, Inflammation
- Trial name
- CHIANTI (NCT05162742)
- Testing
- Colchicine
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Radboud University Medical Center
Aortic Valve Stenosis
IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssion
This study invastigates the effect of icosapent ethyl in patients with aortic valve stenosis.
- Trial name
- SALVAGE (NCT06466278)
- Testing
- Icosapent ethyl
- Where
- Netherlands
- Volunteers
- 110 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Hypertrophic Cardiomyopathy
Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy
The overall aim of this project is to establish potential benefits of a novel lifestyle (physical activity and dietary nitrate) and pharmacological (angiotensin receptor neprilysin inhibitor) interventions in patients with…
- Trial name
- SILICOFCM (NCT03832660)
- Testing
- Lifestyle, Sacubitril/Valsartan
- Where
- 5 sites in Germany, Italy and 2 more
- Volunteers
- 168 people
- Sponsor
- Newcastle University
Heart Valve Disease, Aortic Stenosis
Value of Oral Phytate (InsP6) in the Prevention of Progression of the Cardiovascular Calcifications
Intervention study focused on preventing the progression of aortic valve calcification. Vascular and cardiac calcifications are a marker of risk and poor outcome, especially the severe calcified aortic stenosis and coronary…
- Trial name
- CALCIFICA (NCT01000233)
- Testing
- Phytine (phytate)
- Where
- Spain
- Volunteers
- 250 people
- Sponsor
- Hospital Universitari Son Dureta
Valvular Heart Diseases, Valvular Heart Disease Stenosis and Regurgitation
ECG and CXR for Predicting Cardiovascular Diseases
This retrospective multicenter cohort study aims to develop and validate an artificial intelligence model integrating electrocardiography (ECG) and chest radiography (CXR) to predict future progression of regurgitant valvular…
- Conditions
- Valvular Heart Diseases, Valvular Heart Disease Stenosis and Regurgitation, Regurgitation, Aortic Valve, Regurgitation, Mitral
- Trial name
- NCT07573852
- Where
- China
- Volunteers
- 116,380 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital
AORTIC VALVE DISEASES, Calcification; Heart
Molecular Imaging to Identify Predictors of Aortic Valve Disease Activity
This is a prospective study that aims to develop clinical calculators that will report on the underlying rate of aortic valve calcification.
- Trial name
- NCT07819344
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Aortic Stenosis, Inflammation
Effect of Colchicine on the Progression of Aortic Valve Stenosis - A Pilot Study
COPAS pilot is a pilot single center double blinded randomized study to determine the effect of targeted anti-inflammation therapy using colchicine, on valvular calcification activity using imaging, i.e.
- Trial name
- COPAS-Pilot (NCT05253794)
- Testing
- Colchicine 0.6 mg
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Percutaneous Coronary Revascularization, Coronary Stenosis
Evaluation of Effectiveness and Safety of Hybrid Coronary Revascularization
This study evaluated the effectiveness and safety of Hybrid Coronary Revascularization in real-world practice.
- Conditions
- Percutaneous Coronary Revascularization, Coronary Stenosis, Coronary Artery Disease Progression, Coronary Artery Bypass Grafting
- Trial name
- HCR registry (NCT03788369)
- Testing
- Hybrid Coronary Revascularization
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Seung-Jung Park
Heart Valve Disease, Mitral Valve (MV) Regurgitation
Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease
The objective of this study is to evaluate and predict the progression of moderate cardiac valve stenosis and regurgitation using clinical, biological, echocardiographic, computed tomography (CT), and magnetic resonance imaging…
- Conditions
- Heart Valve Disease, Mitral Valve (MV) Regurgitation, Mitral Valve Disease, Mitral Valve Stenosis
- Trial name
- VALVE-COMPASS (NCT07267117)
- Where
- 15 sites in China
- Volunteers
- 10,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Carotid Artery Stenosis, Hypercholesterolemia
Progression of Carotid Artery Atheroma in Moderately Hypercholesterolemic Subjects
The purpose of this study is to examine the changes in the carotid artery when subjects receive high or low doses of rosuvastatin.
- Trial name
- NCT00654394
- Testing
- Rosuvastatin
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Aortic Stenosis, Calcific
PCSK9 Inhibitors in the Treatment of Calcific Aortic Stenosis
Calcific aortic stenosis (CAS) can cause severe adverse cardiac events, but there are currently no effective drugs that can prevent or delay the progression of the disease.
- Trial name
- PICASO (NCT07256197)
- Testing
- Treatment with PCSK9 inhibitors, Treatment without PCSK9 inhibitors
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Beijing Anzhen Hospital
Renal Artery Obstruction, Kidney Failure
Stenting in Renal Dysfunction Caused by Atherosclerotic Renal Artery Stenosis
Background: Atherosclerotic renal artery stenosis (ARAS) is associated with progressive loss of renal function and is one of the most important causes of renal failure in the elderly.
- Trial name
- NCT00150943
- Testing
- Renal artery stent
- Where
- Netherlands
- Volunteers
- 140 people
- Sponsor
- UMC Utrecht
Ischemic Stroke, Transient Ischemic Attack
Intracranial Artery Stenosis Magnetic Resonance Imaging: Aetiology and Progression
Stroke has become the leading cause of death in China. It has been shown that intracranial artery stenosis (ICAS) plays a key role in Chinese stroke patients.
- Conditions
- Ischemic Stroke, Transient Ischemic Attack, Intracranial Artery Stenosis
- Trial name
- NCT03417063
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tsinghua University
Aortic Valve Stenosis
Randomized Study to Evaluate the Efficacy of Fluvastatin on Inflammatory Markers in Patients With Aortic Stenosis.
Atherosclerosis and aortic stenosis share inflammatory etiopathogenic characteristics in common. We hypothesized that statins therapy would decrease inflammatory markers concentrations in patients with degenerative aortic…
- Trial name
- NCT00404287
- Testing
- Fluvastatin
- Where
- Spain
- Volunteers
- 164 people
- Sponsor
- AORTICA Group
Aortic Stenosis, Imaging
Mechanisms Of Disease Progression in Aortic Stenosis - the MODAS Study
Biomarkers and mechanisms in the progression of aortic valve stenosis are sometimes not sufficiently understood. The current project will take into account image morphological and immunological aspects that predict the…
- Conditions
- Aortic Stenosis, Imaging, Pathogenesis, Disease Progression
- Trial name
- NCT05851209
- Where
- 3 sites in Germany
- Volunteers
- 938 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Cardiovascular Disease (CVD), Heart Failure
Study of the Progression of Chronic Cardiovascular Conditions
This study will collect physiologic data in patients with cardiovascular conditions and observe the natural history of those conditions for research purposes.
- Conditions
- Cardiovascular Disease (CVD), Heart Failure, Aortic Stenosis, Aortic Stenosis Disease
- Trial name
- OCORO (NCT07420907)
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- Prolaio
Carotid Artery Plaque, Arteriosclerosis
Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant
Objectives: Primary: To evaluate the effect of rimonabant 20-mg once daily in comparison with placebo, on the quantitative progression of atherosclerosis as assessed by carotid artery intima-media thickness (CIMT) Secondary: To…
- Conditions
- Carotid Artery Plaque, Arteriosclerosis, Obesity, Metabolic Syndrome X
- Trial name
- AUDITOR (NCT00228176)
- Testing
- Rimonabant
- Where
- 6 sites in United States, Canada and 4 more
- Volunteers
- 661 people
- Sponsor
- Sanofi
Aortic Stenosis, PCSK9 Inhibitor
A Multicenter, Prospective, Randomized Controlled Trial to Evaluate the Efficacy of PCSK-9 Inhibitors in Delaying the Progression of Calcified Aortic Valve Disease
The aim of this clinical trial is to understand whether the drug PCSK9 inhibitor can slow the progression of calcific aortic valve disease and to understand the safety of the drug.
- Conditions
- Aortic Stenosis, PCSK9 Inhibitor, Calcified Aortic Valve Disease
- Trial name
- NCT06996223
- Testing
- The Group A received PCSK9 inhibitor plus statin therapy
- Volunteers
- 316 people
- Sponsor
- Nanfang Hospital, Southern Medical University